Regular Use Effect of Inhaled Ipratropium Bromide on Airway Responsiveness to Methacholine in Well-controlled Asthma
Phase 4
Completed
- Conditions
- Asthma
- Interventions
- Drug: placebo metered dose inhaler
- Registration Number
- NCT04167280
- Lead Sponsor
- University of Saskatchewan
- Brief Summary
Study is looking at the development of tolerance to methacholine following regular use of ipratropium bromide in mild asthmatics.
- Detailed Description
This study is being conducted people with well controlled (mild) asthma to determine if ipratropium bromide taken three times daily for six days (i.e. 2 puffs in the morning, 2 puffs in the afternoon and 2 puffs in the evening) followed by a final dose on the morning of day 7 reduces the effectiveness of this medication on blocking the effect of methacholine challenge.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 12
Inclusion Criteria
- airway responsiveness to methacholine
- adequate baseline lung function
- no respiratory infection or exposure to stimuli that may alter response to methacholine within 4 weeks
Exclusion Criteria
- pregnancy
- current smoker
- requirement for medications other than salbutamol that will interfere with airway response to methacholine
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- CROSSOVER
- Arm && Interventions
Group Intervention Description placebo placebo metered dose inhaler matching bronchodilator inhaler Ipratropium bromide Ipratropium Metered Dose Inhaler 20mcg bronchodilator inhaler
- Primary Outcome Measures
Name Time Method Methacholine PD20 24 hours after last dose dose of methacholine required to induce a 20% fall in FEV1 (volume of air forcefully exhaled in one second)
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
University of Saskatchewan
🇨🇦Saskatoon, Saskatchewan, Canada